Tax
Tax Reconciliation, Federal Statutory Amount
Vertex Pharmaceuticals Tax Reconciliation, Federal Statutory Amount remained flat by 0.0% to $243.78M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 464333333233.3%, from $0.05 to $243.78M. Over 2 years (FY 2023 to FY 2025), Tax Reconciliation, Federal Statutory Amount shows an upward trend with a 6814100.9% CAGR.
Analysis
StatementIncome Statement
SectionTax
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
cop_tax_reconciliation_federal_statutory_amountHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.21 | $0.21 | $975.10M |
| YoY Change | — | +0.0% | >999% |
Range$0.21 – $975.10M
CAGR>999%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak2+ years growth
Tax Reconciliation, Federal Statutory Amount at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's tax reconciliation, federal statutory amount?
- Vertex Pharmaceuticals (VRTX) reported tax reconciliation, federal statutory amount of $243.78M in Q4 2025.
- How has Vertex Pharmaceuticals's tax reconciliation, federal statutory amount changed year-over-year?
- Vertex Pharmaceuticals's tax reconciliation, federal statutory amount increased by 464333333233.3% year-over-year, from $0.05 to $243.78M.
- What is the long-term trend for Vertex Pharmaceuticals's tax reconciliation, federal statutory amount?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's tax reconciliation, federal statutory amount has grown at a 6814100.9% compound annual growth rate (CAGR), from $0.21 to $975.10M.